Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

Blood (2018) 132 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2018-99-112764

Published: 2018

Journal Articles

Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events

Efstathios Kastritis, MD, Aggeliki Laina, MD, Maria Gavriatopoulou, MD, Georgios Georgiopoulos, MD, Evangelos Eleutherakis-Papaiakovou, MD, Fotiou Despina, MD, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Nikolaos Makris, Efstathios Manios, MD, Magdalini Migkou, MD, Dimitrios C. Ziogas, MD, Maria Roussou, MD, Aristea-Maria Papanota, MD, Eleni-Dimitra Papanagnou, Evangelos Terpos, MD PhD, Ioannis P. Trougakos, Kimon Stamatelopoulos, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 3247.

https://doi.org/10.1182/blood-2018-99-113792

Published: 2018

Journal Articles

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Blood (2018) 132 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2018-99-111608

Published: 2018

Journal Articles

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Blood (2018) 132 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2018-99-112851

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

Journal Articles

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, Paolo Milani, Evangelos Terpos, Marco Basset, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Dimitrios C. Ziogas, Elektra Papadopoulou, Constantinos Pamboucas, Meletios A. Dimopoulos, Giovanni Palladini

Blood (2018) 131 (14): 1568–1575.

https://doi.org/10.1182/blood-2017-12-819904

Published: 2018

Includes: Supplemental data

Journal Articles

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Maria Gavriatopoulou, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Maria Roussou, Magdalini Migkou, Dimitrios C. Ziogas, Nikolaos Kanellias, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2018) 131 (4): 464–467.

https://doi.org/10.1182/blood-2017-10-809293

Published: 2018

Journal Articles

Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients

Efstathios Kastritis, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Magdalini Migkou, Dimitra Gika, Despina Fotiou, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Despina Mparmparousi, Anastasia Gatou, Despina Katopi, Efstathios Manios, Michail Liontos, Stavroula Giannouli, Panagiotis Tsirigotis, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 3117.

https://doi.org/10.1182/blood.V130.Suppl_1.3117.3117

Published: 2017

Journal Articles

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Blood (2017) 130 (Supplement 1): 3118.

https://doi.org/10.1182/blood.V130.Suppl_1.3118.3118

Published: 2017

Journal Articles

Natural History and Outcomes of Asymptomatic IgM Monoclonal Gammopathy

Efstathios Kastritis, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Alexandra Papathoma, Ioannis Panagiotidis, Magdalini Migkou, Despina Fotiou, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Marilyn Spyropoulou-Vlachou, Anna Tasidou, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1882.

https://doi.org/10.1182/blood.V130.Suppl_1.1882.1882

Published: 2017

Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Blood (2017) 130 (Supplement 1): 5397.

https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397

Published: 2017

Journal Articles

Molecular Characterization of Waldenström's Macroglobulinemia Patients Using Peripheral Blood Cell-Free Tumor DNA

Tina Bagratuni, PhD, Ioannis Ntanasis-Stathopoulos, Nefeli Mavrianou-Koutsoukou, Christine Liacos, Nikolaos Kanellias, Magdalini Migkou, Dimitrios C. Ziogas, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, MD PhD, Eftathios Kastritis, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1764.

https://doi.org/10.1182/blood.V130.Suppl_1.1764.1764

Published: 2017

Journal Articles

Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients

Maria Gavriatopoulou, Despina Fotiou, Maria Roussou, Magdalini Migkou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Panagiotidis, Dimitra Gika, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, MD PhD, Eftathios Kastritis, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 3152.

https://doi.org/10.1182/blood.V130.Suppl_1.3152.3152

Published: 2017

NARROW

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Natural History and Outcomes of Asymptomatic IgM Monoclonal Gammopathy

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Molecular Characterization of Waldenström's Macroglobulinemia Patients Using Peripheral Blood Cell-Free Tumor DNA

Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only